Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals Inc.
WKN: 881535 / Symbol: REGN / Name: Regeneron / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
684,60 €
-0,76 %
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Guggenheim from $940.00 to $810.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $700.00 price target on the stock, up previously from $600.00.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $943.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at Guggenheim.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $958.00 to $755.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at BMO Capital Markets from $800.00 to $600.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Citigroup Inc. from $700.00 to $650.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $950.00 to $800.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $755.00 to $754.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at BMO Capital Markets from $600.00 to $640.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Truist Financial Corporation from $940.00 to $812.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Rothschild & Co Redburn. They set a "buy" rating and a $890.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Jefferies Financial Group Inc. from $813.00 to $831.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Sanford C. Bernstein from $753.00 to $781.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by analysts at Morgan Stanley from $761.00 to $756.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Citigroup Inc. from $650.00 to $660.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Cantor Fitzgerald from $678.00 to $740.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Guggenheim from $815.00 to $865.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Citigroup Inc. from $660.00 to $700.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for REGN provided by MarketBeat
Neueste Beiträge
StockNews_com in Acadia Pharmaceuticals diskutieren